CHICAGO, United States, May 26, 2026
Cosmos Health Inc., a diversified and vertically integrated global healthcare company, has released ambitious financial guidance for the 2026–2029 period, projecting substantial growth across revenue, profitability, cash generation, and operational expansion. The company announced plans to increase annual revenue from $65.3 million in 2025 to $200.6 million by 2029, representing a remarkable 207% increase and a compound annual growth rate (CAGR) of 32%. The strategic roadmap positions Cosmos Health as an emerging high-margin healthcare platform focused on pharmaceutical distribution, nutraceuticals, manufacturing, biotechnology innovation, AI-driven healthcare technologies, and selective acquisition opportunities.
According to the company, projected gross profit is expected to rise from $7.9 million to $71.2 million, while adjusted EBITDA could increase to $44.2 million by 2029. Cosmos Health also anticipates becoming fully self-funding by 2027, with operating cash flow expected to turn positive and cash reserves projected to reach $62.9 million by the end of the guidance period. Company executives emphasized that the strategy focuses not only on revenue growth but also on transforming the quality of earnings through expansion into higher-margin proprietary healthcare segments and operational efficiencies.
Cosmos Health Expands High-Margin Healthcare Platform
Cosmos Health stated that its long-term growth strategy is built around seven key operational pillars designed to support scalable expansion and stronger profitability. Central to the strategy is a major shift toward higher-margin proprietary products, including the company’s 18 Series nutraceutical platform, Sky Premium Life® food supplements, C-Scrub® antimicrobial cleanser, and the investigational CCX weight management product.
The company also plans to continue expanding contract manufacturing operations through Cana Laboratories, its European Medicines Agency (EMA) licensed and GMP-certified manufacturing subsidiary. Management indicated that current facility utilization remains significantly below total capacity, providing considerable room for future growth as global demand increases for pharmaceuticals, nutraceuticals, medical devices, and healthcare products.
Advertisement
Cosmos Health projects gross profit margins will increase dramatically from 12.1% in 2025 to 35.5% by 2029, driven primarily by increased sales of proprietary products and expanding manufacturing services. Management described this transformation as a structural shift rather than a temporary financial improvement, reflecting broader changes in the company’s healthcare business model.
AI-Driven Healthcare and Biotech Pipeline Fuel Growth
The company is also investing heavily in artificial intelligence-driven healthcare innovation and biotechnology research programs. Through its proprietary Cloudscreen platform, Cosmos Health is using AI-powered drug repurposing technologies to identify new therapeutic opportunities across obesity, diabetes, oncology, and medical devices.
Among the company’s most closely watched pipeline programs is CCX0722, a patent-protected hydrogel-based weight management product designed to support appetite control and satiety. The product is being positioned within the rapidly growing global obesity and weight management market, which industry analysts estimate could approach $299 billion by 2030.
Cosmos Health is additionally advancing research into nanotechnology-based nutraceutical formulations designed to improve bioavailability and efficacy of phytochemical ingredients. These programs align with increasing global demand for preventive healthcare products, functional nutrition, and personalized wellness solutions.
Management stated that operational efficiencies generated through AI-driven automation technologies are expected to reduce targeted operating expenses by up to 30% while improving scalability across manufacturing, warehousing, and distribution systems.
Global Expansion and Acquisition Strategy Accelerate Growth
Cosmos Health continues expanding its international footprint across Europe, the Middle East, the United Kingdom, and North America. The company’s pharmaceutical distribution subsidiary, Cosmofarm, is increasing pharmacy network penetration while leveraging robotic infrastructure and operational automation to improve efficiency and customer profitability.
In parallel, the company plans to pursue selective mergers, acquisitions, and strategic business combinations targeting healthcare assets, product licenses, and proprietary technologies complementary to its existing platform. Management confirmed that strengthening cash flow generation and balance sheet performance are expected to increase financing flexibility for future expansion initiatives.
Chief Executive Officer Greg Siokas stated that the company is approaching a major inflection point, emphasizing that Cosmos Health’s strategy aims to build a diversified, innovation-driven healthcare platform capable of delivering long-term shareholder value while expanding its position across multiple high-growth healthcare sectors.
Source: Cosmos Health press release
